A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung ...

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...

In a Johns Hopkins Children’s Center study, the addition of navitoclax to the standard TB treatment significantly increased ...

A multidisciplinary clinical team led by Professor Bernat Soria from the Institute of Bioengineering at the Miguel Hernández ...

Mar. 13, 2025 — A discovery about how severe COVID-19 damages lung cells suggests that an existing drug could treat lingering respiratory problems not just from COVID but influenza and other ...

Researchers are studying why the energy factories are moving between cells and whether the process can be harnessed to treat ...

Study Links Methylmalonic Acid to Weakening of Immune Cells in Lung Cancer Oct. 31, 2024 — A new study has found a surprising link between high levels of methylmalonic acid and the weakening of ...

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

Most patients who enroll in the Lung-MAP precision medicine trial in non-small cell lung cancer can now be matched to a targeted investigational treatment based on the results of their prior genomic ...

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...